ProVascTec

What ProVascTec does

ProVascTec is a preclinical-stage biotechnology company developing cell therapies for vascular diseases, with its lead program focused on chronic limb-threatening ischemia (CLTI). Founded in March 2023 as a spin-out from University College Cork (UCC) in Ireland and established as an NLC Health venture, the company combines allogeneic mesenchymal stem cell (MSC) therapy with a proprietary biodegradable delivery device designed to enable targeted, high-payload cell delivery to sites of arterial occlusion. Its lead product, nuflo CelTx (also referenced as PulseCLTI), aims to restore blood flow through paracrine signaling and neovascular network formation, with the clinical objective of preventing lower-limb amputations in patients with severe peripheral artery disease.

The platform addresses documented historic failure modes in cell therapy — rapid cell death upon delivery, imprecise targeting, and the lack of scalable allogeneic cell sources — by coupling MSCs with a polymer chemistry- and structural design-based delivery system. ProVascTec leverages the low immunogenicity of allogeneic MSCs to pursue off-the-shelf manufacturing with consistent treatment outcomes. While the immediate development focus is CLTI, the company's own materials indicate that disease-specific design adaptations are intended to extend the platform across inflammation, cancer, and age-related disease indications.

ProVascTec is pre-commercial and has not generated product revenue. It has secured over €4.6 million in combined non-dilutive grant funding and equity, including a €2.5 million Disruptive Technologies Innovation Fund (DTIF) award in September 2025, an EU Horizon Europe grant exceeding €2.1 million in 2024, and an oversubscribed pre-seed financing round in December 2024. Its intended go-to-market is direct sales to tertiary and quaternary care hospitals, targeting interventional cardiologists, vascular surgeons, and interventional radiologists. The company collaborates with an international consortium — Arrotek Medical (device development and regulatory), Empa (materials science), and Cellcolabs (manufacturing) — to advance its lead program through preclinical testing and toward regulatory approval for clinical trials.

Name

ProVascTec

Legal name

ProVascTec

Website

https://provasctec.com

Company type

Private

Founded year

2023

Operating status

Operating

Headcount range

1–10 employees

Short description

ProVascTec is a preclinical-stage Irish biotech developing allogeneic MSC-based cell therapies delivered via a proprietary biodegradable device for chronic limb-threatening ischemia. A 2023 UCC spin-out, it aims to prevent limb amputations by promoting targeted neovascular regeneration in patients with severe peripheral artery disease.

Ownership category

akta.pro rank

Product category

Regenerative Medicine Cell Therapy

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Surgical Appliance and Supplies Manufacturing (339113)

SIC

Biological Products, (No Disgnostic Substances) (2836), Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Cell Therapy Developers (Allogeneic/Off-the-shelf) (HLAAABAB)

akta.pro secondary industries

Stem Cell Therapies (MSC/iPSC/HSC-derived) (HLAAABAE), Stem Cell–Based Regenerative Therapies (HLAAAGAA)

Keywords

• Cell therapy treatments
• Regenerative medicine platform
• Stem cell delivery devices
• Critical limb ischemia therapy
• Vascular medicine biotherapeutics

Headquarters

HQ city

Cork

HQ country

Ireland

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Infrastructure

Revenue model

1. Cell Therapy Product Sales: ProVascTec will generate revenue through the sale of its proprietary cell therapy products, specifically nuflo CelTx for critical limb ischemia. The company is developing an off-the-shelf allogeneic MSC-based therapy that, upon regulatory approval, will be commercialized to hospitals and vascular medicine centers for treatment of chronic limb-threatening ischemia.

Pricing tiers

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Core offering

ProVascTec develops off-the-shelf allogeneic mesenchymal stem cell (MSC) therapies combined with a proprietary biodegradable delivery device for targeted placement of high cell payloads at sites of medical need. The lead product, nuflo CelTx (also referenced as PulseCLTI), targets chronic limb-threatening ischemia (CLTI) by promoting neovascular network formation through paracrine signaling to restore blood flow and prevent limb amputations. The platform is designed for adaptation across multiple indications including inflammation, cancer, and age-related diseases through disease-specific device design.

Product overview

ProVascTec is a University College Cork spinout developing targeted cell therapies for vascular diseases. The company's platform centers on proprietary delivery technology for mesenchymal stem cells (MSCs), with the lead product nuflo CelTx targeting chronic limb-threatening ischemia (CLTI). The technology enables precision placement of high-dose MSC payloads at arterial occlusion sites, promoting neovascular network formation through paracrine signaling to bypass blockages and restore blood flow, potentially preventing limb amputations.

Differentiator

Problem solved

Functional benefit

Products and services

• nuflo CelTx (also referenced as PulseCLTI) Off-the-shelf allogeneic mesenchymal stem cell (MSC) therapy combined with a proprietary biodegradable delivery device for the treatment of chronic limb-threatening ischemia (CLTI). The product targets precision placement of high MSC payloads at arterial occlusion sites, where the cells release paracrine factors that trigger vascular remodeling and neovascular network formation to bypass arterial blockages and restore blood flow, with the goal of preventing limb amputations.

Quantifiable outcome

• Promotes neovascular network formation that bypasses main artery obstruction through collateral vessel connections, improving downstream blood flow

Segments2 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Four partnerships are on record, tiered core.

• Arrotek Medical LtdcoreStrategic or Co-development Partner · 25 September 2025Consortium partner in the PULSE-CLTI project funded by DTIF. Arrotek Medical provides expertise in medical device development and regulatory approval support for the PulseCLTI therapy, working alongside ProVascTec and UCC researchers to advance prototype development and preclinical testing.
• University College Cork (UCC)coreStrategic or Co-development PartnerProVascTec is a spin-out from UCC. The partnership includes research collaboration, access to facilities, and board representation through Kevin Dalton (Commercialisation Manager at UCC Innovation). UCC provides IP commercialization support and spin-out formation expertise.
• Empa (Swiss Federal Laboratories for Materials Science and Technology)coreStrategic or Co-development PartnerInternational research partner in the Eurostars-funded nuflo CelTx project and EU Horizon Europe research. Empa contributes expertise in materials science and bioengineering for the cell therapy delivery platform development.
• CellcolabscoreStrategic or Co-development PartnerInternational consortium partner from Sweden in the Eurostars-funded nuflo CelTx project. Contributes to the decentralized, collaborative manufacturing model for ProVascTec's lead product offering.

Scale indicators4 records

Recent moves7 records

Expansion highlights6 records

Broad incumbents

• TiGenix (now part of Takeda): TiGenix developed the first allogeneic cell therapy (Cx601, darvadstrocel) approved in Europe, providing a relevant large-incumbent comparable for allogeneic cell therapy development, manufacturing, and regulatory strategy, though in a different indication (perianal fistulas in Crohn's).

Direct peers

• Mesoblast: Mesoblast is a clinical-stage MSC therapy developer with allogeneic, off-the-shelf cell products across inflammatory and cardiovascular indications, including CLI programs. It is directly comparable to ProVascTec in cell type, allogeneic manufacturing model, and target disease areas.
• Pluristem Therapeutics: Pluristem develops placenta-derived MSC therapies (PLX-PAD) and has run multiple clinical programs in critical limb ischemia, making it the most directly comparable peer in terms of indication, cell type, and therapeutic approach to ProVascTec's nuflo CelTx.
• Athersys / Healios K.K. Athersys developed MultiStem (multipotent adult progenitor cell therapy) and ran programs in critical limb ischemia and other ischemic indications, providing a direct comparison point on clinical execution risk and outcomes in CLI cell therapy.

Emerging players

• Lineage Cell Therapeutics: Lineage Cell Therapeutics develops allogeneic cell therapies, including programs for vascular and ischemic conditions. Comparable to ProVascTec as a clinical-stage allogeneic cell therapy developer with regenerative medicine focus.
• Capricor Therapeutics: Capricor develops cell-based therapies (CAP-1002, cardiosphere-derived cells) for cardiac and inflammatory indications, sharing ProVascTec's positioning as a clinical-stage regenerative cell therapy company with cardiovascular focus.
• Cynata Therapeutics: Cynata develops iPSC-derived MSC (Cymerus) therapies for indications including critical limb ischemia and graft-versus-host disease. Comparable to ProVascTec as an emerging allogeneic MSC developer with a scalable manufacturing angle.
• Caladrius Biosciences: Caladrius has historically pursued cell-based therapies for cardiovascular disease, including CLTI programs (HONEDRA in Japan), making it a directly relevant peer in MSC-based vascular regenerative medicine.
• BioCardia: BioCardia develops catheter-based delivery systems for cell and gene therapies to the heart, providing a relevant peer in cell therapy delivery technology and a potential adjacency to ProVascTec's proprietary delivery device approach.
• Stempeutics Research: Stempeutics commercialized Stempeucel, a pooled bone marrow-derived MSC product approved in India for CLI. It is a directly comparable MSC-for-CLI peer, with real-world launch experience relevant to ProVascTec's regulatory and commercialization trajectory.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Funding overview

Funding rounds2 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about ProVascTec